MOU with ProSciento to cooperate toward the mutual goal of providing the healthcare industry
JNPMEDI
JNPMEDI and ProSciento, a CRO based in California, signed a memorandum of understanding (MOU) to strengthen the global service competitiveness of clinical trials and promote cooperative projects. Through this business agreement, it was agreed to discuss the promotion of clinical trials in the United States and joint clinical trials for major countries in the Asia-Pacific region in the future.
JNPMEDI (CEO Kwun-ho Jeong), a medical data platform company, and ProSciento (CEO Marcus Hompesch), a clinical research organization (CRO) have entered into an agreement to cooperate toward the mutual goal of providing the healthcare industry with a comprehensive and effective clinical trial operation.
JNPMEDI (CEO Kwun-ho Jeong) (Right), ProSciento (CEO Marcus Hompesch)(Left)
JNPMEDI (CEO Kwun-ho Jeong), a medical data platform company, and ProSciento (CEO Marcus Hompesch), a clinical research organization (CRO) have entered into an agreement to cooperate toward the mutual goal of providing the healthcare industry with a comprehensive and effective clinical trial operation.
Through the agreement, JNPMEDI and ProSciento will jointly expand their footprint within the US and APAC clinical trials markets.
By cooperating with ProSciento, a leading CRO in the metabolic field, JNPMEDI will seek deeper insight into the US market. Together with Maven Clinical Cloud, an end-to-end clinical data management system, the partnership seeks to positively disrupt the global clinical trial sector. The initial steps of the cooperation will focus on effectively strategizing the offering of Maven Clinical Cloud to US sponsors. In the long term, the partnership will explore expansion into Singapore and APAC.
Upon signing the MOU ProSciento’s CEO Marcus Hompesch expressed, “ProSciento is excited to partner with JNPMEDI, a company with a competitive toolset in the eClinical Solutions space.” “The partnership will work closely to strategize and implement a path through the global clinical trials market,” he continued.
JNPMEDI’s CEO Kwun-ho Jeong answered, “we are thankful to have partnered with ProSciento, an active player in the biggest market for healthcare.” He ended by saying, “With this agreement, we will continue to advance our product and aggressively expand globally.”
Established in 2003, ProSciento is a clinical research organization specializing in metabolic diseases such as NASH, Diabetes, and Obesity. ProSciento has conducted more phase 1/2 clinical trials for type 1, type 2, and NASH than any other US provider.